GlassScriptPhysician profile
Uma F Iyer
NPI 1558399899
$815.86
in general payments reported to CMS, 2019-2025
23 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.95 · 2020: $31.75 · 2022: $147 · 2023: $110 · 2024: $190 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.35 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $130.60 | 2019-2024 | Darzalex, Talvey, Tecvayli |
| Seagen INC. | $99.95 | 2025 | |
| Pfizer INC. | $82.68 | 2019-2025 | |
| Astellas Pharma US INC | $75.59 | 2023-2025 | Padcev, Xtandi |
| Amgen INC. | $48.46 | 2019-2022 | |
| Csl Behring | $43.05 | 2022-2025 | Afstyla, Idelvion |
| Octapharma USA, INC. | $41.57 | 2024-2025 | Octagam Immune Globulin (Human) |
| Taiho Oncology, INC. | $32.67 | 2024-2025 | |
| Celgene Corporation | $25.83 | 2024 | Pomalyst |
| Novartis Pharmaceuticals Corporation | $23.84 | 2024 | |
| Eisai INC. | $23.55 | 2022 | |
| Puma Biotechnology, INC. | $22.36 | 2023 | |
| Genentech USA, INC. | $22.22 | 2022 | |
| Abbvie INC. | $19.95 | 2023 | |
| Gilead Sciences, INC. | $16.92 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $16.25 | 2023 | Brukinsa |
| Merck Sharp & Dohme LLC | $16.08 | 2020 | |
| Incyte Corporation | $14.99 | 2022 | |
| Genzyme Corporation | $13.91 | 2024 | |
| Mirati Therapeutics, INC. | $13.63 | 2024 | Krazati |
| Aurobindo Pharma USA, INC. | $13.51 | 2019 | |
| Apellis Pharmaceuticals, INC. | $11.70 | 2022 | |
| Biocartis US, INC | $6.55 | 2023 | Idylla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Iyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.